METHOD OF IMPROVING LOWER URINARY TRACT SYMPTOMS
The embodiments include methods of improving the symptoms of mammals having LUTS, using compositions containing Fexapotide Triflutate and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering Fexapotide Triflutate intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or with a carrier to a mammal in need thereof.
1 . A method of improving the symptoms of mammals having Lower Urinary Tract Symptoms (LUTS) comprising: (i) identifying mammals having LUTS and do not have benign prostatic hyperplasia (BPH); and (ii) administering to the mammal having LUTS but not BPH a therapeutically effective amount of SEQ ID NO. 1 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), wherein the method improves the mean obstructive voiding symptoms (MOVS) measured by the International Prostate Symptom Score (IPSS), by more than 30%, when compared to administering a control composition that does not contain SEQ ID NO. 1.
2 . The method of claim 1 , wherein the method comprises administering a therapeutically effective amount of SEQ ID NO. 1 as claimed in claim 1 and a carrier.
3 . The method of claim 1 , wherein SEQ ID NO. 1 is administered more than once.
4 . The method of claim 1 , wherein SEQ ID NO. 1 is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intramuscularly, intrathecally, intranasally, intratumorally, topically, and transdermally.
5 . The method of claim 1 , wherein the method improves the mean obstructive voiding symptoms (MOVS) measured by IPSS, within the range of from about 30% to about 150%.
6 . The method of claim 5 , wherein the method improves the mean obstructive voiding symptoms (MOVS) measured by IPSS, within the range of from about 35% to about 125%.
7 . The method of claim 6 , wherein the method improves the mean obstructive voiding symptoms (MOVS) measured by IPSS, within the range of from about 45% to about 105%.
8 . The method of claim 1 , wherein the method improves the mean obstructive voiding symptoms (MOVS) measured by IPSS, by more than 300%, when compared to the MOVS of patients who received oral medication known to be useful in treating benign prostatic hyperplasia (BPH).
9 . The method of claim 1 , wherein the method improves the mean irritative storage symptoms (MISS) measured by IPSS, by more than 20%, when compared to administering a control composition that does not contain SEQ ID NO. 1.
10 . The method of claim 9 , wherein the method improves the mean irritative storage symptoms (MISS) measured by IPSS by an amount within the range of from about 20% to about 50%.
11 . The method of claim 10 , wherein the method improves the mean irritative storage symptoms (MISS) measured by IPSS by an amount within the range of from about 25% to about 40%.
12 . The method of claim 11 , wherein the method improves the mean irritative storage symptoms (MISS) measured by IPSS by an amount within the range of from about 30% to about 35%.